Sustainability is gaining significant attention across corporate agendas. From boardrooms to investor calls, language around environmental responsibility and resilience has become the norm. Yet, the latest 2025 Global Biopharma Index reveals a paradox: while sustainability is widely recognized as critical, progress is stalling. Why?
Eco-friendly ambitions collide with biopharma business realities
In its third biennial installment, the 2025 Global Biopharma Index ― which surveyed 1250 biopharma executives across 22 countries ― introduced environmental sustainability as an independent measure of industry performance. Despite innovation booms and digital transformation, the most recent data shows a weakening biopharma ecosystem with the index score falling to 5.96, down from 6.08 in 2023 and 6.60 in 2021.
So, what did the results tell us about sustainability across the industry? In short, it’s being deprioritized and, ultimately, that comes at a cost.
- 49% of firms are behind on revenue and profitability targets, creating pressure to prioritize short-term financial performance over long-term environmental goals.
- Talent shortages and regulatory uncertainty are slowing progress in advanced modalities, and these pressures are diverting resources away from sustainability initiatives.
- Geopolitical volatility is reshaping supply chains, pushing companies to focus on resilience and cost efficiency rather than decarbonizing distribution.
- While sustainability is acknowledged as a strategic imperative, ambition is outpacing capability. Many organizations lack the infrastructure, expertise, and incentives to deliver meaningful change.
But industry leaders need to know that operational emissions reduction is possible even in challenging markets. Over the past three years, Cytiva has cut its scope 1 and 2 emissions by almost half while simultaneously transitioning our major global manufacturing sites to nearly 100% renewable electricity.
The solution could be investing early in capability building and sustainable practices. Cytiva, for example, has embedded eco-design reviews into every new product introduction, ensuring engineers and scientists consider carbon, materials, and end-of-life impacts from the earliest design phase — a model that builds sustainability into day-to-day practice rather than keeping it as an add-on or specialty.
Financial targets drive an industry disconnect
The slowdown in sustainability progress isn’t due to indifference; it’s a matter of competing realities. Economic pressures weigh heavily on the industry. In an environment marked by investor caution and market volatility, sustainability often slips from being a strategic imperative to a discretionary ambition.
Boards and shareholders, once vocal champions of environmental commitments, are now applying less pressure than in previous years. The urgency of meeting short-term revenue and profitability targets overshadows long-term goals, creating a tension between financial survival and environmental stewardship.
Compounding this challenge is a fragmented policy landscape. Regulatory frameworks differ dramatically across regions, and the lack of harmonization breeds uncertainty. Companies hesitate to make bold investments in sustainability when compliance requirements remain unpredictable. The result is a cautious approach ― incremental steps rather than transformative leaps ― because no organization wants to risk misalignment with future regulations.
Talent scarcity adds another layer of complexity. Sustainability isn’t just a philosophy; it’s a technical discipline requiring expertise in life cycle analysis, green chemistry, and circular manufacturing. These skills are in short supply, and competition for qualified professionals is fierce. Without the right talent, even the most ambitious strategies falter, leaving organizations unable to operationalize their commitments.
Finally, the tension between short-termism and long-term value persists. The Global Biopharma Index highlights that high-growth firms are embedding environmental sustainability into digital innovation and collaborative ecosystems. Countries such as South Korea, India, and the United Kingdom are climbing the ranks by investing in advanced manufacturing and ecosystem strength. These examples prove that progress is possible ― but only when sustainability is treated as a growth driver rather than a compliance checkbox.
Practical action is also emerging in areas like materials innovation. In early 2026, Cytiva is transitioning widely used filtration devices to ISCC PLUS–certified biobased resins, reducing reliance on fossil‑based plastics and helping laboratories take measurable steps toward their own emissions goals.
What needs to change for sustainability success?
If the biopharma industry is to reverse the slowdown and place sustainable business practices higher on the agenda, it must start by embedding it into the very core of corporate strategy. Sustainability can’t remain a peripheral initiative or a compliance exercise; it needs to be treated as a growth driver, a catalyst for innovation, and competitive advantage because, ultimately, it is!
Investment in talent and technology is equally critical. The future of sustainable biopharma will be shaped by expertise in green innovation and the ability to harness advanced tools such as artificial intelligence for monitoring, optimization, and predictive modelling. These technologies can transform sustainability from an aspirational goal into a measurable, actionable reality. But without the right skills and infrastructure, even the most ambitious plans will remain theoretical.
Collaboration must also transcend borders. While in-region-for-region is accelerating in response to geopolitical pressures, the challenges of climate change and resource scarcity are global. No single company or country can solve these issues alone. Collective solutions such as shared standards, joint ventures, and cross-industry partnerships are essential to drive systemic change and avoid fragmented progress. Through collaborations such as its single‑use plastics recycling program with Polycarbin, Cytiva is enabling customers to divert laboratory plastics from landfill and build more circular research workflows — illustrating how collective action amplifies environmental impact.
Finally, incentives need to be realigned. Sustainability metrics shouldn’t sit in isolation from financial performance; they should be woven into sourcing strategy, executive action, and investor confidence frameworks. When leadership accountability and shareholder expectations converge on sustainability outcomes, ambition turns into action. Linking environmental goals to performance sends a clear message: sustainability is not optional, it’s integral to success.
The sustainable business opportunities ahead
The sustainability slowdown is not a failure, it’s a signal; a signal that sustainability can’t survive as a siloed initiative. It must be woven into the fabric of biopharma’s innovation engine… and momentum is building. At several of our Cytiva sites, associates have uncovered and delivered thousands of metric tons of CO₂ savings through grassroots operational improvements alone, reinforcing that sustainable business transformation is rarely top down — it’s cultural.
Those who act now will not only futureproof their operations, but they’ll also lead the next wave of competitive advantage.